Search research articles
Contact Us
Filters
Showing results (71-80 of 90) with videos related to
Page
of 9
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
January 16, 2019
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study
Shirish M Gadgeel, Rimas V Lukas, Jerome Goldschmidt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 10, 2004
A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities
Arno J Mundt, Srinivasan Vijayakumar, John Nemunaitis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 18, 2020
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Robert Jotte, Federico Cappuzzo, Ihor Vynnychenko, et al.
JAMA
|
October 23, 2003
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial
Mark G Kris, Ronald B Natale, Roy S Herbst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2015
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Giorgio Scagliotti, Joachim von Pawel, Silvia Novello, et al.
The Lancet. Oncology
|
May 25, 2019
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West, Michael McCleod, Maen Hussein, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2018
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study
Leora Horn, Scott N Gettinger, Michael S Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2006
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function
Alain C Mita, Christopher J Sweeney, Sharyn D Baker, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 16, 2018
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study
David R Gandara, Joachim von Pawel, Julien Mazieres, et al.
The New England Journal of Medicine
|
June 5, 2018
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 90) with videos related to
Sort By:
Page
of 9
Lung Cancer (Amsterdam, Netherlands)
|
January 16, 2019
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study
Shirish M Gadgeel, Rimas V Lukas, Jerome Goldschmidt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 10, 2004
A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities
Arno J Mundt, Srinivasan Vijayakumar, John Nemunaitis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 18, 2020
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Robert Jotte, Federico Cappuzzo, Ihor Vynnychenko, et al.
JAMA
|
October 23, 2003
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial
Mark G Kris, Ronald B Natale, Roy S Herbst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2015
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Giorgio Scagliotti, Joachim von Pawel, Silvia Novello, et al.
The Lancet. Oncology
|
May 25, 2019
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West, Michael McCleod, Maen Hussein, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2018
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study
Leora Horn, Scott N Gettinger, Michael S Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2006
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function
Alain C Mita, Christopher J Sweeney, Sharyn D Baker, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 16, 2018
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study
David R Gandara, Joachim von Pawel, Julien Mazieres, et al.
The New England Journal of Medicine
|
June 5, 2018
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, et al.
Page
of 9